DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Recruiting

Phase 2

BI 764532DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Sponsor:

Boehringer Ingelheim

Code:

NCT05882058

Conditions

Small Cell Lung Carcinoma

Neuroendocrine Neoplasms

Extra-pulmonary Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BI 764532, dose 1

BI 764532, dose 2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-25. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-06-24.